These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7295752)

  • 1. Unusual familial lipoprotein C-III associated with apolipoprotein C-III-O preponderance.
    Maeda H; Uzawa H; Kamei R
    Biochim Biophys Acta; 1981 Sep; 665(3):578-85. PubMed ID: 7295752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum lipoproteins and apolipoproteins in rats with streptozotocin-induced diabetes.
    Bar-On H; Roheim PS; Eder HA
    J Clin Invest; 1976 Mar; 57(3):714-21. PubMed ID: 175093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms of apolipoprotein C-III in two cases with sialidase deficiency.
    Maeda H; Uzawa H; Nakamura N; Nakashima Y; Goto I
    Life Sci; 1981 Nov; 29(20):2065-9. PubMed ID: 7311733
    [No Abstract]   [Full Text] [Related]  

  • 4. Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects.
    Huff MW; Fidge NH; Nestel PJ; Billington T; Watson B
    J Lipid Res; 1981 Nov; 22(8):1235-46. PubMed ID: 7320634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concentrations of apolipoproteins B, C-I, C-II, C-III and E in sera from normal men and their relation to serum lipoprotein levels.
    Carlson LA; Holmquist L
    Clin Chim Acta; 1982 Sep; 124(2):163-78. PubMed ID: 6754139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes.
    Wang CS; Alaupovic P; Gregg RE; Brewer HB
    Biochim Biophys Acta; 1987 Jul; 920(1):9-19. PubMed ID: 3109493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult xanthogranulomatosis associated with abnormal plasma apolipoprotein levels.
    Bergman R; Friedman-Birnbaum R; Aviram M; Katz I; Kerner H; Brook JG
    Clin Exp Dermatol; 1990 Sep; 15(5):372-5. PubMed ID: 2225543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women.
    Chiuve SE; Martin LA; Campos H; Sacks FM
    J Clin Endocrinol Metab; 2004 May; 89(5):2207-13. PubMed ID: 15126543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia.
    von Eckardstein A; Holz H; Sandkamp M; Weng W; Funke H; Assmann G
    J Clin Invest; 1991 May; 87(5):1724-31. PubMed ID: 2022742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
    Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV
    J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of lipids, lipoproteins, and apolipoproteins in Menkes' disease.
    Blackett PR; Lee DM; Donaldson DL; Fesmire JD; Chan WY; Holcombe JH; Rennert OM
    Pediatr Res; 1984 Sep; 18(9):864-70. PubMed ID: 6483510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the plasma lipoprotein distribution of apolipoproteins C-II, C-III1, C-III2 and apolipoprotein B after heparin-induced lipolysis.
    Nestel PJ; Huff MW; Billington T; Fidge NH
    Biochim Biophys Acta; 1982 Jul; 712(1):94-102. PubMed ID: 7115750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
    Chan DC; Watts GF; Nguyen MN; Barrett PH
    Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):590-6. PubMed ID: 16410456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demonstration of an abnormality of C apoprotein of very low density lipoprotein in patients with gout.
    Macfarlane DG; Midwinter CA; Dieppe PA; Bolton CH; Hartog M
    Ann Rheum Dis; 1985 Jun; 44(6):390-4. PubMed ID: 4015201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis.
    Forte TM; Nichols AV; Krauss RM; Norum RA
    J Clin Invest; 1984 Nov; 74(5):1601-13. PubMed ID: 6501564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein EBethesda: a new variant of apolipoprotein E associated with type III hyperlipoproteinemia.
    Gregg RE; Ghiselli G; Brewer HB
    J Clin Endocrinol Metab; 1983 Nov; 57(5):969-74. PubMed ID: 6578216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Separation and purification of human apolipoproteins A-I and C-III by chromatofocusing].
    Cheng B
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1993 Aug; 15(4):280-5. PubMed ID: 8168208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.